Key Takeaways:
Fulcrum Therapeutics is handing control of its Nasdaq listing to migraine startup Slate Medicines after scrapping its lead drug last month.
Fulcrum Therapeutics will merge with migraine startup Slate Medicines in an all-stock transaction that leaves Slate investors with 95 percent of the combined company, after Fulcrum discontinued its lead drug candidate in July.
"Migraine remains one of the most prevalent and disabling neurological diseases, yet millions of patients continue to be underserved by existing therapies," Gregory Oakes, chief executive officer of Slate Medicines, said.
The transaction, announced Monday, values Slate at $350 million and Fulcrum at $31.3 million, with the combined company to trade on Nasdaq under the ticker "SLTE." Slate secured an oversubscribed $245 million private placement led by Frazier Life Sciences, with participation from Forbion, RA Capital Management, Deep Track Capital, Foresite Capital, OrbiMed, RTW Investments and Mingxin Capital. Fulcrum expects to contribute about $20.3 million in net cash and pay a $270 million cash dividend to its pre-merger stockholders before closing, which is expected in the fourth quarter of 2026.
The combined cash is expected to fund operations into 2029, supporting Slate's lead candidate SLTE-1009, a subcutaneous anti-PACAP/VIP monoclonal antibody for migraine prevention, through Phase 1 and Phase 2 studies. Initial pharmacokinetic and safety data are expected in mid-2027, with a second program, SLTE-2100, a bispecific antibody targeting PACAP/VIP and CGRP, entering clinical trials in the second half of 2027.
Fulcrum, a clinical-stage biopharmaceutical company focused on rare hematological disorders, said last month it discontinued development of its lead drug candidate. The all-stock merger follows an evaluation of strategic alternatives, according to Alex C. Sapir, Fulcrum's president and chief executive officer.
"Following our evaluation of strategic alternatives, we are pleased to announce this transaction with Slate, which we believe represents the best path forward for our stockholders and a compelling opportunity to participate in the development of a portfolio of next generation migraine therapeutics," Sapir said.
Slate's lead asset targets two neuropeptides — pituitary adenylate cyclase-activating peptide (PACAP) and vasoactive intestinal peptide (VIP) — that play foundational roles in migraine pathophysiology. The approach builds on clinical validation of PACAP-ligand blockade: Lundbeck's bocunebart, an intravenous anti-PACAP antibody, showed a statistically significant reduction in monthly migraine days in its Phase 2b PROCEED trial, while Amgen's AMG301, a PAC1 receptor-binding antibody, failed to beat placebo in a Phase 2 study.
SLTE-1009 was engineered with half-life extension to enable subcutaneous dosing with potential for quarterly administration, a differentiation from bocunebart's intravenous delivery. In functional cellular assays, Slate said SLTE-1009 demonstrated equivalent potency to bocunebart on PACAP and enhanced blockade of VIP.
The market for CGRP antagonists, the current standard of care for migraine prevention, generated roughly $5 billion in 2025 sales and is expected to reach $12.5 billion in peak class sales by 2033, according to Persistence Market Research. Yet pivotal studies in chronic migraine show only about half of patients achieve a 50 percent reduction in monthly migraine days, leaving room for new entrants.
For Fulcrum stockholders, the deal offers a cash dividend of about $270 million before closing in exchange for a roughly 5 percent stake in the combined company. The merger is subject to stockholder and regulatory approvals, including an SEC registration statement and Hart-Scott-Rodino antitrust clearance, with closing expected in the fourth quarter of 2026.
This article is for informational purposes only and does not constitute investment advice.
